PTPRD gene associated with blood pressure response to atenolol and resistant hypertension

Objective: The aim of this study is to identify single-nucleotide polymorphisms (SNPs) influencing blood pressure (BP) response to the &bgr;-blocker atenolol. Methods: Genome-wide association analysis of BP response to atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension in the pharmacogenomic evaluation of antihypertensive responses study. Forty-two polymorphisms with P less than 10−5 for association with either diastolic or systolic response to atenolol monotherapy were validated in four independent groups of hypertensive individuals (total n = 2114). Results: In whites, two polymorphisms near the gene PTPRD (rs12346562 and rs1104514) were associated with DBP response to atenolol (P = 3.2 × 10−6 and P = 5.9 × 10−6, respectively) with directionally opposite association for response to hydrochlorothiazide in another group of 228 whites (P = 0.0018 and P = 0.00012). A different polymorphism (rs10739150) near PTPRD was associated with response to atenolol in 150 black hypertensive individuals (P = 8.25 × 10−6). rs12346562 had a similar trend in association with response to bisoprolol (a different &bgr;-blocker) in 207 Finnish men in the genetics of drug responsiveness in essential hypertension study. In addition, an intronic single-nucleotide polymorphism (rs4742610) in the PTPRD gene was associated with resistant hypertension in whites and Hispanics in the international verapamil SR trandolapril study (meta-analysis P = 3.2 × 10−5). Conclusion: PTPRD was identified as a novel locus potentially associated with BP response to atenolol and resistant hypertension in multiple ethnic groups.

[1]  Talicia Tarver,et al.  HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION , 2014 .

[2]  G. Bakris,et al.  Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension , 2014, Journal of hypertension.

[3]  J. Holmes,et al.  Health, United States, 2013 : with special feature on prescription drugs , 2014 .

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  Sungha Park,et al.  A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients , 2013, Journal of hypertension.

[6]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[8]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[9]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[10]  Romer A. Gonzalez-Villalobos,et al.  JAK-STAT and the renin-angiotensin system , 2012, JAK-STAT.

[11]  E. Boerwinkle,et al.  Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response , 2012, Journal of Translational Medicine.

[12]  E. Demerath,et al.  A genome-wide association study of aging , 2011, Neurobiology of Aging.

[13]  D. Nicolae,et al.  Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals , 2011, Diabetologia.

[14]  E. Lange,et al.  Genome‐Wide Association Study of Anthropometric Traits and Evidence of Interactions With Age and Study Year in Filipino Women , 2011, Obesity.

[15]  G. Abecasis,et al.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes , 2010, Genetic epidemiology.

[16]  E. Boerwinkle,et al.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. , 2010, American journal of hypertension.

[17]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[18]  Fuu-Jen Tsai,et al.  A Genome-Wide Association Study Identifies Susceptibility Variants for Type 2 Diabetes in Han Chinese , 2010, PLoS genetics.

[19]  L. Almasy,et al.  Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study. , 2009, Blood.

[20]  Chris Sander,et al.  The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers , 2009, Proceedings of the National Academy of Sciences.

[21]  E. Boerwinkle,et al.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. , 2009, American heart journal.

[22]  W. Elliott.  Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2009 .

[23]  M J Ball,et al.  Healthcare Informatics , 2009, Encyclopedia of Database Systems.

[24]  Daniel W. Jones,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[25]  T. Strandberg,et al.  Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). , 2007, American journal of hypertension.

[26]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[27]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[28]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[29]  Julie A. Johnson,et al.  Collection of Genomic DNA by the Noninvasive Mouthwash Method for Use in Pharmacogenetic Studies , 2002, Pharmacotherapy.

[30]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[31]  B Waeber,et al.  Individual responses to converting enzyme inhibitors and calcium antagonists. , 1988, Hypertension.

[32]  E. Freis,et al.  Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. , 1983, The American journal of medicine.